Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Embody vs TrueMe

Embody
Graded #52

Higher grade

vs+8.799999999999997
TrueMe
Graded #171

Lower grade

The verdict

Embody takes it — 76.2/100 to 67.4/100.

Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEmbody +26
87
61
Dose & formulationEmbody +6
83
77
Clinical oversightEmbody +5
83
78
Labs & monitoringEmbody +2
54
52
FulfillmentEmbody +12
93
81
Contract termsTrueMe +20
25
45
Embody · left barTrueMe · right bar

The numbers

MetricEmbodyTrueMe
WeighScore76.2/10067.4/100
GradeCC
Scorecard rank#52#171
Semaglutide$79/mo (all doses, promotional rate, compounded)$159/mo (compounded)
Tirzepatide$129/mo (all doses, promotional rate, compounded)$189/mo (compounded)
CoverageAll 50 states6 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Embody

Graded #52 · C

Strengths

  • Among the lowest flat rates in the compounded segment — $79/mo semaglutide and $129/mo tirzepatide injection at every dose
  • Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
  • Available in all 50 states with no insurance friction
  • 24/7 unlimited clinician messaging and dose-adjustment support included
  • Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine

Where it loses points

  • The $79 flat rate relies on an auto-applied promo 'locked forever' — list price in the terms is $199/mo and reviewers allege the lock isn't honored
  • Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Pharmacy partners not publicly named — compounding source transparency is limited
  • Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
TrueMe

Graded #171 · C

Strengths

  • One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
  • Same price at every dose, so the cost does not climb as a provider titrates the dose upward
  • Full pricing is published up front — no intake form is required before you can see what you will pay
  • Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
  • Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas

Where it loses points

  • Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
  • Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
  • You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
  • The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
  • A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard